Representatives of Moderna Biotech UK and NHS England will also be questioned by the inquiry, led by crossbench peer Baroness ...
The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine ...
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...
As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...
Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...
12don MSN
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain ...
The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...
The amended lawsuit, filed in July 2022, sought a court order requesting that the agency reconsider granting authorization ...
it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of its coronavirus vaccine program. In that vein, let's learn ...
Robert F. Kennedy Jr. made claims during his Senate confirmation hearing on issues including vaccines, pesticides and Lyme ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback